Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by OilGoldon May 30, 2012 11:40pm
366 Views
Post# 19963875

Flami-1

Flami-1

Flami-1 Exploration Well
Drilling the Flami #1 well on the Llanos 27 Block in the Llanos Basin of Colombia commenced on April 23, 2012. The well is being drilled with the Saxon 132 1,500 horsepower rig and has a planned total depth of 10,000 feet. The well is programmed to test the hydrocarbon potential of the Mirador and Une formations with secondary targets being the Carbonera and Gacheta formations. The gross budget for drilling the well is US$10 million with a testing budget of US$4 million. The Company is paying 50% of the gross amount to earn a private participating interest of 45.275% before payout and 34.25% after payout. As of May 30, 2012, the well has been drilled to a depth of 9,000 feet at the top of the Mirador formation and intermediate casing and cement has been set. The remainder of the well is expected to commence drilling on June 1, 2012. Once target depth has been reached, logs will be run to determine which formations are to be tested, a liner and cement will be set, and testing operations will commence.

 

Hopefully by  next week they  will TD of 10,000.

 

Cheeeeers.

Bullboard Posts